Letter: Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2016;40:240-7).
作者信息
Kim Jin Hwa
机构信息
Department of Endocrinology and Metabolism, Chosun University Hospital, Chosun University School of Medicine, Gwangju, Korea.
出版信息
Diabetes Metab J. 2016 Aug;40(4):334-5. doi: 10.4093/dmj.2016.40.4.334.
Abstract
摘要
相似文献
1
Letter: Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2016;40:240-7).信函：瑞巴派特对2型糖尿病患者胃肠道症状的影响（《糖尿病代谢杂志》2016年；40:240 - 247）
Diabetes Metab J. 2016 Aug;40(4):334-5. doi: 10.4093/dmj.2016.40.4.334.
2
Response: Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2016;40:240-7).回应：瑞巴派特对2型糖尿病患者胃肠道症状的影响（《糖尿病代谢杂志》2016年；40:240 - 247）
Diabetes Metab J. 2016 Aug;40(4):336-7. doi: 10.4093/dmj.2016.40.4.336.
3
Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus.瑞巴派特对2型糖尿病患者胃肠道症状的影响。
Diabetes Metab J. 2016 Jun;40(3):240-7. doi: 10.4093/dmj.2016.40.3.240. Epub 2016 Apr 21.
4
Letter: The Necessity of the Simple Tests for Diabetic Peripheral Neuropathy in Type 2 Diabetes Mellitus Patients without Neuropathic Symptoms in Clinical Practice ( 2018;42:442-6).信函：2型糖尿病无神经病变症状患者临床实践中糖尿病周围神经病变简易检测的必要性（2018年；42卷：442 - 446页）
Diabetes Metab J. 2018 Dec;42(6):544-545. doi: 10.4093/dmj.2018.0238.
5
Letter: Effects of High-Dose α-Lipoic Acid on Heart Rate Variability of Type 2 Diabetes Mellitus Patients with Cardiac Autonomic Neuropathy in Korea (Diabetes Metab J 2017;41:275-83).信函：高剂量α-硫辛酸对韩国2型糖尿病合并心脏自主神经病变患者心率变异性的影响（《糖尿病代谢杂志》2017年；41:275 - 83）
Diabetes Metab J. 2017 Oct;41(5):417-419. doi: 10.4093/dmj.2017.41.5.417.
6
Letter: Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2015;39:342-7).信函：2型糖尿病患者中双肽基肽酶-4抑制剂疗效的预测因素（《糖尿病代谢杂志》2015年；39:342 - 347）
Diabetes Metab J. 2015 Oct;39(5):444-5. doi: 10.4093/dmj.2015.39.5.444. Epub 2015 Oct 22.
7
Letter: Prevalence and Risk Factors of Gastroesophageal Reflux Disease in Patients with Type 2 Diabetes Mellitus ( 2016;40:297-307).信函：2型糖尿病患者胃食管反流病的患病率及危险因素（2016年；40:297 - 307）
Diabetes Metab J. 2016 Oct;40(5):418-419. doi: 10.4093/dmj.2016.40.5.418. Epub 2016 Oct 12.
8
Letter: Efficacy of Moderate Intensity Statins in the Treatment of Dyslipidemia in Korean Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2017;41:23-30).信函：中等强度他汀类药物对韩国2型糖尿病患者血脂异常的治疗效果（《糖尿病代谢杂志》2017年；第41卷：第23 - 30页）
Diabetes Metab J. 2017 Apr;41(2):150-151. doi: 10.4093/dmj.2017.41.2.150.
9
Letter: genome-wide association study identifies two novel Loci with sex-specific effects for type 2 diabetes mellitus and glycemic traits in a korean population (diabetes metab j 2014;38:375-87).信函：全基因组关联研究在韩国人群中鉴定出两个对2型糖尿病和血糖性状具有性别特异性效应的新基因座（《糖尿病与代谢杂志》2014年；38:375 - 87）
Diabetes Metab J. 2014 Dec;38(6):484-6. doi: 10.4093/dmj.2014.38.6.484.
10
Letter: Features of Long-Standing Korean Type 2 Diabetes Mellitus Patients with Diabetic Retinopathy: A Study Based on Standardized Clinical Data (Diabetes Metab J 2017;41:393-404).信函：基于标准化临床数据的韩国长期2型糖尿病视网膜病变患者的特征：一项研究（《糖尿病代谢杂志》2017年；41:393 - 404）
Diabetes Metab J. 2017 Dec;41(6):492-493. doi: 10.4093/dmj.2017.41.6.492.
本文引用的文献
1
Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus.瑞巴派特对2型糖尿病患者胃肠道症状的影响。
Diabetes Metab J. 2016 Jun;40(3):240-7. doi: 10.4093/dmj.2016.40.3.240. Epub 2016 Apr 21.
2
7. Approaches to Glycemic Treatment.7. 血糖治疗方法。
Diabetes Care. 2016 Jan;39 Suppl 1:S52-9. doi: 10.2337/dc16-S010.
3
Diabetic gastroparesis: what we have learned and had to unlearn in the past 5 years.糖尿病性胃轻瘫：过去 5 年中我们学到和不得不摒弃的知识。
Gut. 2010 Dec;59(12):1716-26. doi: 10.1136/gut.2009.199703. Epub 2010 Sep 25.
4
Metoclopramide, an increasingly recognized cause of tardive dyskinesia.甲氧氯普胺是迟发性运动障碍一个越来越被认可的病因。
J Clin Pharmacol. 2008 Mar;48(3):379-84. doi: 10.1177/0091270007312258. Epub 2008 Jan 25.
5
Drug Insight: from disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide.药物洞察：从运动紊乱到运动失调——甲氧氯普胺的临床益处与法医学风险综述
Nat Clin Pract Gastroenterol Hepatol. 2006 Mar;3(3):138-48. doi: 10.1038/ncpgasthep0442.
6
Oral erythromycin and the risk of sudden death from cardiac causes.口服红霉素与心脏原因导致的猝死风险
N Engl J Med. 2004 Sep 9;351(11):1089-96. doi: 10.1056/NEJMoa040582.
7
Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults.糖尿病相关胃肠道症状的患病率：一项基于15000名成年人的人群调查。
Arch Intern Med. 2001 Sep 10;161(16):1989-96. doi: 10.1001/archinte.161.16.1989.
8
Diabetes and the gastrointestinal tract.糖尿病与胃肠道
Gastroenterol Clin North Am. 1998 Dec;27(4):861-74, vi-vii. doi: 10.1016/s0889-8553(05)70035-2.
9
A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis.一项关于口服胃复安治疗糖尿病胃轻瘫的多中心安慰剂对照临床试验。
Diabetes Care. 1983 Sep-Oct;6(5):463-7. doi: 10.2337/diacare.6.5.463.
Zotero 插件